Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of T. MAN PHARMA Apixaban 5 mg vs Eliquis 5 mg in healthy Thai volunteers (fasting)
TCTR20230208003Phase 1Unknown
- Sponsor
- Bio-innova
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Status: unknown.
02
Drugs
apixaban
Beyond the preview
Go deeper on TCTR20230208003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230208003.